1e
19
1
49
2
2
18
1b
1d
18
39
87
1d
2 29
1d
25
Janos L. Tanyi, M.D., Ph.D.
78
87
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
28
9e
3
70
Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
11
Department: Obstetrics and Gynecology
4
1
b
1d
46
Contact information
55
4
3
3
3
2
4
b
1f
55
Department of Obstetrics and Gynecology
34 Jordan Center for Gynecologic Cancer at Penn
2d Perelman Center for Advanced Medicine
46 3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
26
34 Jordan Center for Gynecologic Cancer at Penn
2d Perelman Center for Advanced Medicine
46 3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
2e
Office: 215-662-3318
32 Fax: 215-349-5849
24
95
32 Fax: 215-349-5849
24
Email:
janos.tanyi@uphs.upenn.edu
12
janos.tanyi@uphs.upenn.edu
13
Education:
21 9 M.D. 1c (Summa cum Laude) c
4e University of Debrecen, Faculty of Medicine, Hungary , 1993.
21 a Ph.D. 1c (Summa cum Laude) c
73 Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
c
3
3
3
3
8d
Permanent link21 9 M.D. 1c (Summa cum Laude) c
4e University of Debrecen, Faculty of Medicine, Hungary , 1993.
21 a Ph.D. 1c (Summa cum Laude) c
73 Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
c
2 29
21
1e
1d
24
2b
29
27
23
397 Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med Jan 2025.
12f Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Nov 2024.
10b Li S, Oatman E, Tanyi J, Kim SH, Cory L, Mangalmurti NS.: Detection of HPV DNA on Red Blood Cells. Oral presentation. Mid-Atlantic Gynecologic Oncology Society Conference. Atlanta, GA. Oct 2024.
231 Tanyi JL, O’Hara M, Hexner E, Marshall A, Jadlowsky J, Farrelly O, Carly Stein C, Anne Chew A, Emily Dowd E, Vanessa Gonzalez V, Joseph Fraietta J, Gabriela Plesa G, Neil Sheppard N, Carl June C.: Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer. Oral Presentation. Advancing Gene and Cell Therapies for Cancer Conference. Philadelphia, PA Oct 2024.
1ae Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol Jul 2024.
1e4 Pohlmann P R, Abdou Y, Johnson M, Maziarz RT, Specht J, Dees E Claire, Yuan Y, Tanyi J, Angelos M, Gill S, Wetzel J, Cushing D, Klichinsky M, Condamine T, and Reiss K: A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. ASCO Chicago, IL (TIP- Trail in progress) Jun 2024.
1fd Simpkins F, Nasioudis D, Wethington S, Martin L. Tanyi, J, Latif N, Torigian D, Omran D, Rodriguez D, Smith S, Dean E, Domchek S, Drapkin R, Shih I, Brown, E, Hwang W, Armstrong D, Gaillard S, Giuntoli R, Liu J: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). ASCO, 2024, Annual Meeting. Chicago, IL Jun 2024.
14e Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Huang J, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Tavana O, Chan HM, Hu X, Zhang L.: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv 1f May 2024.
200 Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study. Ann Surg Oncol. Page: doi: 10.1245/s10434-024-15307-8. Online ahead of print, May 2024.
2c
7
1d
1f
Selected Publications
149 de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, Wang TL, Shih IM, Schwartz LE, Kim S, Morgan MA, Tanyi JL, Burns KH, Lengyel E, Parra-Herran C, Godwin AK, Walt DR, Drapkin R 2 a9 : LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ Precis Oncol Mar 2025.397 Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med Jan 2025.
12f Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Nov 2024.
10b Li S, Oatman E, Tanyi J, Kim SH, Cory L, Mangalmurti NS.: Detection of HPV DNA on Red Blood Cells. Oral presentation. Mid-Atlantic Gynecologic Oncology Society Conference. Atlanta, GA. Oct 2024.
231 Tanyi JL, O’Hara M, Hexner E, Marshall A, Jadlowsky J, Farrelly O, Carly Stein C, Anne Chew A, Emily Dowd E, Vanessa Gonzalez V, Joseph Fraietta J, Gabriela Plesa G, Neil Sheppard N, Carl June C.: Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer. Oral Presentation. Advancing Gene and Cell Therapies for Cancer Conference. Philadelphia, PA Oct 2024.
1ae Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol Jul 2024.
1e4 Pohlmann P R, Abdou Y, Johnson M, Maziarz RT, Specht J, Dees E Claire, Yuan Y, Tanyi J, Angelos M, Gill S, Wetzel J, Cushing D, Klichinsky M, Condamine T, and Reiss K: A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. ASCO Chicago, IL (TIP- Trail in progress) Jun 2024.
1fd Simpkins F, Nasioudis D, Wethington S, Martin L. Tanyi, J, Latif N, Torigian D, Omran D, Rodriguez D, Smith S, Dean E, Domchek S, Drapkin R, Shih I, Brown, E, Hwang W, Armstrong D, Gaillard S, Giuntoli R, Liu J: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). ASCO, 2024, Annual Meeting. Chicago, IL Jun 2024.
14e Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Huang J, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Tavana O, Chan HM, Hu X, Zhang L.: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv 1f May 2024.
200 Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study. Ann Surg Oncol. Page: doi: 10.1245/s10434-024-15307-8. Online ahead of print, May 2024.
2c